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Engagement of CD47 Inhibits the Contact
Hypersensitivity Response Via the Suppression of
Motility and B7 Expression by Langerhans Cells
Xijun Yu1, Atsushi Fukunaga1, Hiroshi Nagai1, Shuntaro Oniki1, Nakayuki Honma2, Masamitsu Ichihashi3,
Takashi Matozaki4, Chikako Nishigori1 and Tatsuya Horikawa1
CD47 is a membrane-associated glycoprotein that suppresses the function of immune cells. We previously
reported that Langerhans cells (LCs) express Src homology 2 domain-containing protein tyrosine phosphatase
substrate 1 (SHPS-1), a ligand for CD47, which plays an important role in the regulation of their motility. In this
study, we show that LCs also express CD47, and that ligation of CD47 with SHPS-1-Fc fusion protein in vivo
diminishes the development of the contact hypersensitivity response. We further demonstrate that CD47
engagement affects immune functions of LCs. CD47 engagement in vivo significantly inhibits the emigration of
LCs from the epidermis into draining lymph nodes following treatment with haptens and tumor necrosis factor-
a. The emigration of dendritic cells from skin explants into the medium and the chemotaxis of murine XS52
dendritic cells were significantly reduced by treatment with SHPS-1-Fc or an anti-CD47 mAb. Under explant
culture system, SHPS-1-Fc treatment suppressed the expression of CD80 and CD86 of LCs. These effects on LCs
and contact hypersensitivity response of CD47 ligation were reversed by treatment with pertussis toxin. These
results suggest that the ligation of CD47 inhibits the migration of LCs and the expression of B7 costimulatory
molecules, which results in inhibition of the contact hypersensitivity response.
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INTRODUCTION
Contact hypersensitivity (CHS) is an inflammatory immune
response, which is induced by the application of haptens on
the skin. Exposure to antigenic stimulation by haptens
stimulates Langerhans cells (LCs) in the epidermis, which
results in their migration from the epidermis into the draining
lymphoid tissues where they initiate naı¨ve T cells by means of
major histocompatibility complex–antigen complexes
(Grabbe and Schwarz, 1998; Kimber et al., 2000). During
this migration, LCs undergo maturational changes that
involve increases in the production of chemokines and the
expression of cell surface molecules, such as major histo-
compatibility complex class II, ICAM-1, CD80, and CD86
(B7 molecules), which play critical roles in the development
of CHS (Aiba and Katz, 1990; Cumberbatch et al., 1991;
Grabbe and Schwarz, 1998; Kimber et al., 2000). The
migration and maturation of LCs thus appear to be essential
events in the development of CHS. The migration of LCs
appears to be triggered by various stimuli, including hapten
application, the transfer of skin from in vivo to in vitro culture
medium, and the injection of cytokines such as tumor
necrosis factor-a (TNF-a) and IL-1b, which are believed to
play essential roles in the induction of LC migration following
hapten application (Macatonia et al., 1987; Cumberbatch
and Kimber, 1992; Cumberbatch et al., 1997a). LC migration
is upregulated by various other factors, including IL-16, IL-18,
integrin a6, CD40, and prostaglandin E2, whereas IL-10 and
prostaglandin D2 downregulate LC migration (Price et al.,
1997; Wang et al., 1999; Angeli et al., 2001; Cumberbatch
et al., 2001; Stoitzner et al., 2001; Jolles et al., 2002;
Kabashima et al., 2003). CCR7 in coordination with its ligand
CCL19 and CCL21 appears to be indispensable in mobilizing
LCs from the epidermis into lymphatics in the dermis and
then into draining lymph nodes (Ohl et al., 2004).
CD47, also known as integrin-associated protein, is a
50 kDa cell-surface glycoprotein that is ubiquitously ex-
pressed in many cell types and is functionally associated with
integrins (Brown and Frazier, 2001; Oldenborg, 2004). CD47
is composed of an immunoglobulin-like extracellular do-
main, five putative transmembrane-spanning segments, and a
short cytoplasmic tail. One of the ligands for CD47 is
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thrombospondin-1, which has been shown to modulate a
variety of cellular events including immune responses.
Thrombospondin-1 has been shown to inhibit the production
of proinflammatory cytokines including TNF-a and IL-12 by
human dendritic cells (DCs) (Doyen et al., 2003). Ligation of
CD47 on T lymphocytes by thrombospondin-1 suppresses the
proliferation of the cells, whereas its ligation by a4b1 integrin,
another ligand for thrombospondin-1, activates adhesion,
chemotaxis, and matrix metalloproteinase expression of T
cells (Li et al., 2002). Another ligand for CD47 appears to be
Src homology 2 domain-containing protein tyrosine phos-
phatase substrate 1 (SHPS-1), also known as signal regulatory
protein (SIRP) a1, which is a transmembrane glycoprotein
with three immunoglobulin-like extracellular domains and
two immunoreceptor with tyrosine-based inhibition motifs in
the cytoplasmic domain (Fujioka et al., 1996; Kharitonenkov
et al., 1997; Seiffert et al., 2001). The SHPS-1–CD47 system is
a novel type of cell–cell communication, which bidirection-
ally modulates immune responses. SHPS-1 is expressed by
macrophages, DCs, neutrophils, and neuronal cells, whereas
CD47 is ubiquitously expressed on all hematopoietic cells
and other cell types (Brown and Frazier, 2001; Oldenborg,
2004). Ligation of CD47 by a mAb to CD47 or by 4N1K, a
peptide derived from the CD47-binding site of thrombos-
pondin-1, has been shown to inhibit the development of Th1
effector cells, to downregulate the expression of IL-12R by T
lymphocytes, to induce T-cell anergy, and to reduce cytokine
production and the maturation of DCs (Avice et al., 2001;
Latour et al., 2001). CD47 also plays a critical role in
regulating the clearance of hematopoietic cells, including red
blood cells and lymphocytes (Oldenborg et al., 2000; Blazar
et al., 2001). Engagement of CD47 has been shown to
suppress transendothelial and transepithelial migration of
neutrophils (Cooper et al., 1995; Parkos et al., 1996). The
SHPS-1–CD47 system may play a pivotal role in regulating
leukocyte–epithelial interactions (Zen and Parkos, 2003). So
far, limited data are available on the function of the SHPS-
1–CD47 system in immune cells in vivo.
We show in this study that in vivo treatment with a CD47
ligand significantly inhibits the development of the CHS
response. We further show that treatment with a CD47 ligand
inhibits not only the migration of LCs from the epidermis into
draining lymph nodes but also the expression of B7
costimulatory molecules, CD80 and CD86.
RESULTS
Epidermal LCs in situ, XS52 cells, and keratinocytes express
CD47
FACS analyses of freshly isolated epidermal cells revealed
that I-Ab-positive cells and I-Ab-negative cells in the
epidermis are recognized by a CD47 mAb (Figure 1a).
SHPS-1-Fc is a chimera protein of human Fc portion of
human IgG and mouse SHPS-1, the ligand for CD47. Similar
to the CD47 mAb, SHPS-1-Fc also binds to I-Ab-positive and
I-Ab-negative cells (Figure 1b). The binding of SHPS-1-Fc to
the plasma membrane of LC-like XS52 cells was confirmed
by FACS (Figure 1c). G361, a human melanoma cell line that
does not express mouse CD47, did not bind to SHPS-1-Fc
(Figure 1d) or CD47 mAb (not shown). Preincubation with
SHPS-1-Fc reduced the binding of the CD47 mAb to XS52
cells by a maximum of 70% (Figure 1e). Preincubation with
CD47 mAb reduced the binding of SHPS-1-Fc to XS52 cells
by a maximum of 90% (Figure 1f). These observations
indicate that the binding of SHPS-1-Fc is specific to CD47.
Treatment with SHPS-1-Fc in vivo during the sensitization phase
but not challenge phase reduces the CHS response
Because it has been shown that ligation of CD47 modulates
immune functions in vitro, we examined whether treatment
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Figure 1. CD47 is expressed on murine epidermal LCs or XS52 cells. FACS
analysis of an epidermal cell suspension shows that the majority of I-Ab-
positive cells (a) express CD47 and (b) bind to SHPS-1-Fc. The left panels of
(a) or (b) depict anti-rat IgG-FITC or human IgG-Fc, respectively. (c) The
histogram obtained by FACS analysis using SHPS-1-Fc and FITC-conjugated
goat anti-human IgG indicates a significant expression of CD47 on the cell
surface of XS52 cells (dashed line) as compared to human IgG-Fc (solid line).
(d) G361, a human melanoma cell line that does not express mouse CD47,
did not show binding of SHPS-1-Fc (dashed line) or control human IgG-Fc
(solid line) on its cellular surface. (e) Preincubation with SHPS-1-Fc reduced
the binding of anti-mouse CD47 mAb on XS52 cells (dotted line) compared to
that without preincubation with SHPS-1-Fc (bold line). (f) Preincubation with
anti-mouse CD47 mAb reduced the binding of SHPS-1-Fc on XS52 cells
(dotted line) compared to that without preincubation with anti-mouse CD47
mAb (bold line).
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with SHPS-1-Fc in vivo affects the development of CHS.
When mice were sensitized by treatment with control human
IgG plus DNFB, significant ear swelling with multiple
infiltrating leukocytes was observed (Figure 2c and d)
compared to unsensitized controls (Figure 2a and d).
However, treatment with SHPS-1-FcþDNFB significantly
reduced the ear swelling after challenge compared to
controls treated with human IgG-FcþDNFB (Figure 2b and
d). Treatment with SHPS-1-Fc before DNFB challenge did not
affect the increment of ear swelling (SHPS-1-Fc, 227729 mm
vs control human IgG-Fc, 232748 mm).
In vivo SHPS-1-Fc treatment reduces the number of hapten-
bearing cells in lymph nodes
Based on the observation that treatment with SHPS-1-Fc
reduced the development of CHS, we hypothesized that
engagement of CD47 in vivo would influence the motility of
LC. To test this hypothesis, we first analyzed draining lymph
nodes of mice, which had been treated with SHPS-1-Fc and
then painted with FITC. Pretreatment with SHPS-1-Fc (60 mg/
ear) decreased the number of FITCþ /I-Abþ cells migrating
into the draining lymph nodes 24 hours after the FITC
painting compared with mice pretreated with human IgG-
Fc as a control (Figure 3a). In each of four separate
experiments, there was a statistically significant decrease in
FITCþ /I-Abþ cells in the draining lymph nodes of the SHPS-
1-Fcþ FITC treated group compared with the human IgG-
Fcþ FITC-treated group (Figure 3c). To further confirm the
inhibitory effect of treatment with SHPS-1-Fc on the migra-
tion of LCs into the lymph nodes, we assessed the number of
FITCþ /Langerinþ cells in the draining lymph nodes after the
application of FITC. Similar to FITCþ /I-Abþ cells, we
observed a significant decrease in FITCþ /Langerinþ cells in
the draining lymph nodes of the SHPS-1-Fcþ FITC-treated
group compared with the human IgG-Fcþ FITC-treated group
(Figure 3b and d).
In vivo treatment with SHPS-1-Fc fusion protein prevents a
decrease of LC density in the epidermis after epicutaneous
hapten application and TNF-a treatment
To examine whether SHPS-1-Fc affects the migration of LCs
from the epidermis into the dermis, the epidermis was
obtained 24 hours after the epicutaneous application of
DNFB following treatment with SHPS-1-Fc. Consequently,
the population of I-Abþ cells in the epidermis was decreased
in mice treated with human IgG-FcþDNFB (Figure 4c)
compared to mice without DNFB treatment (Figure 4a),
whereas the reduction of the I-Abþ cell population in the
200
160
120
Ea
r s
w
e
llin
g 
(m
)
80
40
0 Human IgG-Fc
Vehicle
Human IgG-Fc
DNFB
SHPS-1-Fc
DNFB
**
a
d
b c
Figure 2. Treatment with SHPS-1-Fc in vivo suppressed the development of
CHS. (b) SHPS-1-Fc or (a, c) human IgG-Fc was injected intradermally into the
right ear before the application of 0.5% DNFB solution. After 5 days, 0.2%
DNFB was applied on the left ear and ear swelling was evaluated 24 hours
after application. (c) The infiltration of leukocytes was profound in mice of
IgG-FcþDNFB sensitization group, whereas (a) minimum or (b) reduced
infiltrates were observed in IgG-Fc without sensitization or in SHPS-1-
FcþDNFB groups, respectively. (d) Ear swelling for SHPS-1-Fc treatment is
significantly decreased compared with human IgG-Fc (**Po0.01; n¼ 5).
Error bars indicate standard deviations (SDs). Bar¼100 mm.
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Figure 3. The reduction of hapten-bearing cells in draining lymph nodes by
in vivo treatment with SHPS-1-Fc. SHPS-1-Fc and human IgG-Fc were
injected intradermally before FITC application. Draining lymph nodes were
collected 24 hours after the application of 3% FITC, and lymph node cells
were stained for I-Ab or Langerin. A total of 100,000 and 30,000 cells were
analyzed using FACScaliber for FITCþ /I-Abþ and FITCþ /Langerinþ cells,
respectively. Representative data from FACS analyses and the percentage of
(a) FITCþ /I-Abþ cells and (b) FITCþ /Langerinþ cells are shown. The mean
numbers of (c) FITCþ /I-Abþ cells and (d) FITCþ /Langerinþ cells in the
draining lymph nodes after intradermal injection of SHPS-1-Fc plus FITC
application were significantly lower compared with that after injection of
human IgG-Fc plus FITC application (**Po0.01; n¼4). Error bars indicate
SDs.
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SHPS-1-FcþDNFB-treated group was significantly inhibited
(Figure 4b and d). Similarly, SHPS-1-Fc reduced the decrease
in the number of I-Abþ cells in the epidermis after TNF-a
treatment (Figure 4e).
Emigration of LCs from epidermal explants to the culture
medium is inhibited by SHPS-1-Fc or by a CD47 mAb
It has been shown that epidermal LCs emigrate into the
culture media during skin explant culture (Ratzinger et al.,
2002). To investigate the influence of ligation of CD47 on the
migration of epidermal LCs, we cultured murine epidermal
explants with graded concentrations of SHPS-1-Fc (0.3–30mg/
ml) or a CD47 mAb (0.2–20mg/ml). LCs emigrate sponta-
neously from murine epidermal explants into the culture
medium over a period of 48 hours. We confirmed by FACS
analysis that 80% of the retrieved cells were positive for I-Ab
(not shown). When SHPS-1-Fc was added to the culture
medium, a significant reduction in the number of LCs
retrieved from the culture medium was observed at concen-
trations of 3–30 mg/ml (Figure 5a). The addition of a CD47
mAb similarly reduced the number of LCs retrieved from the
culture medium at concentrations of 2–20 mg/ml (Figure 5b). It
has been well documented that Gi protein is associated with
CD47, and that a Gi/o inhibitor, pertussis toxin, inhibits
CD47-mediated cellular response (Frazier et al., 1999). We
therefore investigated whether pertussis toxin could suppress
the inhibitory effect of CD47 ligation on the motility of LC.
Treatment with pertussis toxin significantly reversed the
inhibitory effect of SHPS-1-Fc on LC migration into the
culture medium (Figure 5c).
The chemotaxis of IL-4-treated XS52 cells is attenuated by
SHPS-1-Fc and by a CD47 mAb
Because immature XS52 cells do not respond to stimulation
with macrophage inflammatory protein (MIP)-3b, we used
mature XS52 cells in the chemotaxis assay as previously
described (Fukunaga et al., 2004). To obtain mature XS52
cells, they were cultured in complete RPMI supplemented
with GM-CSF and IL-4 for 9 days (then named mature XS52
cells). Mature XS52 cells were attracted to rMIP-3b as
assessed by the chemotaxis assay, whereas SHPS-1-Fc or a
CD47 mAb significantly inhibited the MIP-3b-induced
transmigration in dose-dependent manners (Figure 6a and
b). The addition of pertussis toxin significantly reversed the
inhibitory effect of SHPS-1-Fc on LC transmigration (Figure
6c). SHPS-1-Fc or CD47 mAb did not affect the survival of
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Figure 4. The inhibitory effect of SHPS-1-Fc treatment on the reduction of
I-Abþ LCs in the epidermal sheets induced by DNFB and rTNF-a treatment.
SHPS-1-Fc or human IgG-Fc was intradermally injected into mouse ears in
combination with DNFB application. After 24 hours, epidermal sheets were
obtained and I-Abþ cells were visualized using immunofluorescence.
Representative images of the LC population in the epidermis are shown:
(a) human IgG-Fc without DNFB treatment group; (b) SHPS-1-Fc plus DNFB
treatment group; and (c) human IgG-Fc plus DNFB treatment group.
Bar¼20 mm. (c, d) Pretreatment with human IgG-Fc and DNFB application
caused a 36.2% reduction in the I-Abþ LC density. (b, d) Pretreatment with
SHPS-1-Fc and DNFB application suppressed the reduction in the I-Abþ LC
density by 11.2%. Data for the combined treatment of SHPS-1-Fc and DNFB
were significant compared with the combined treatment of human IgG-Fc and
DNFB (**Po0.01; n¼6). Error bars indicate SDs. (e) rTNF-a or PBS was
injected intradermally. After 1 hour, the epidermis was stained for I-Abþ , and
LCs were counted using a microscope. The combined injection of human
IgG-Fc and rTNF-a caused a 36.3% reduction in the I-Abþ LC density. The
combined injection of SHPS-1-Fc and rTNF-a attenuated the reduction in the
I-Abþ LC density by 17.6%. Data for the combined injection of SHPS-1-Fc
and rTNF-a were significant compared with the combined injection of human
IgG-Fc and rTNF-a (**Po0.01; n¼6). Error bars indicate SDs.
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Figure 5. The emigration of LCs is inhibited by SHPS-1-Fc or a rat
anti-mouse CD47 mAb. Epidermis was separated from dermis by dispase
treatment and then placed in medium with (a) SHPS-1-Fc (0.3–30mg/ml) or
human IgG-Fc (30 mg/ml) and (b) rat anti-mouse CD47 mAb (0.2–20 mg/ml)
or rat IgG (20 mg/ml). Emigrated LCs were counted in the medium after
48 hours. The inhibition was statistically significant at 3–30 mg/ml of
SHPS-1-Fc (**Po0.01; n¼ 6) and at 2–20 mg/ml of rat anti-mouse CD47
mAb (**Po0.01; n¼ 6). (c) Pertussis toxin (PT; 100 ng/ml) significantly
restored the inhibition of LCs emigration by SHPS-1-Fc (3 mg/ml) treatment
(**Po0.01; n¼ 6). Error bars indicate SDs.
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XS52 cells for 24 hours, as confirmed by the Trypan blue
exclusion test (not shown).
Treatment with SHPS-1-Fc downregulates the expression of
CD80 and CD86
As B7 costimulatory molecules, CD80 and CD86, play
essential roles in the development of CHS, we next
questioned whether treatment with SHPS-1-Fc would affect
the expression of these costimulatory molecules. It has been
shown that LCs increase expression of CD86 during explant
culture (Ohl et al., 2004). To study the expression of CD86,
we used the epidermal explant system in which SHPS-1-Fc
inhibits the migration of LCs from the epidermal explant into
the culture media. The explants were collected from the
culture wells 24 hours after the incubation and were stained
for I-Ab and CD86. Explant cultures increased the expression
of CD86 in I-Abþ cells in the epidermal explants (Figure 7a,
upper left and upper right) compared with in situ (Figure 7a,
lower left and lower right), whereas treatment with SHPS-1-
Fc inhibited the increase of CD86 expression (Figure 7a,
middle left and middle right). We assessed the CD86-positive
area in each I-Abþ cell by computer image analysis (NIH
image) and observed a statistically significant reduction of
CD86 expression (Figure 7b). Similarly, CD80 expression was
reduced by the addition of SHPS-1-Fc to the culture medium
during the explant culture, although the intensity of the
expression was weaker than CD86 (Figure 7c). The reduction
of CD86 expression was again reversed by treatment with
pertussis toxin (Figure 7d). To further confirm the inhibitory
effect of CD47 ligation on the B7 expression of LCs, we
analyzed the expression of B7 on the emigrated cells into the
medium during skin explant culture. SHPS-1-Fc reduced the
expression of CD80 (Figure 8a) and CD86 (Figure 8b) on the
I-A-bearing emigrated cells. These results indicate that
ligation of CD47 by SHPS-1-Fc reduces the expression of
B7 molecules.
Pertussis toxin reverses the attenuated CHS response elicited by
SHPS-1-Fc treatment
Based on the finding that pertussis toxin reverses the
inhibitory effect of SHPS-1-Fc on the motility and the
expression of costimulatory molecules of LCs, we examined
whether pertussis toxin could block the inhibitory effect of
SHPS-1-Fc on the development of CHS. We pretreated the
mice with pertussis toxin 2 hours before the treatment with
SHPS-1-Fc, and then sensitized the mice. This procedure
significantly reversed the inhibitory effect of SHPS-1-Fc on
the development of the CHS response (Figure 9).
DISCUSSION
Although accumulating evidence has revealed that the SHPS-
1–CD47 system modulates immune systems (Cooper et al.,
1995; Parkos et al., 1996; Oldenborg et al., 2000; Avice
et al., 2001; Brown and Frazier, 2001; Blazar et al., 2001;
Latour et al., 2001; Seiffert et al., 2001; Zen and Parkos,
2003; Oldenborg, 2004), there is limited information about
the effects of ligation of these molecules on T-cell-mediated
immune responses in vivo. Because LCs express CD47, we
hypothesized that engagement of CD47 may modulate LC
functions and consequently the development of CHS. We
showed here that in vivo treatment with SHPS-1-Fc inhibits
the development of the CHS response, a representative
immune response in which antigen-primed T cells mediate
the inflammation. As the migration of LCs from the epidermis
into the draining lymph nodes is a critical event in the
sensitization phase of CHS, we sought to address the
possibility that CD47 engagement downregulates the migra-
tion of LC. We found that the engagement of CD47 with
SHPS-1-Fc reduced the motility of LCs triggered by haptens,
by TNF-a and by transferring the epidermis from in vivo to
culture medium. LC migration into draining lymph nodes
elicited by FITC painting on the skin was significantly
reduced by treatment with SHPS-1-Fc. As the migration of
LCs into draining lymph nodes is a key event in generating
antigen-specific memory T cells and the consequently
developing CHS, suppression of LC motility could be one
reason why treatment with SHPS-1-Fc attenuates develop-
ment of the CHS response during the sensitization phase.
We further observed that SHPS-1-Fc or a CD47 mAb
significantly reduced the upregulated expression of B7
molecules on the surface of LCs during skin explant culture.
It has been shown that transferring skin from in vivo to in vitro
culture medium induces an upregulated expression of CD86
by LCs (Ohl et al., 2004), similar to what occurs following
hapten application in vivo (Nuriya et al., 1996). Thus, skin
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Figure 6. The chemotaxis of XS52 cells is inhibited by SHPS-1-Fc or a rat
anti-mouse CD47 mAb. XS52 cells were cultured in complete RPMI
supplemented with 10 ng/ml GM-CSF and 10 ng/ml IL-4 for 9 days, and
chemotaxis for MIP-3b was assessed. A dose-dependent reduction in the
number of migrating matured-XS52 cells was observed when (a) SHPS-1-Fc or
(b) rat anti-mouse CD47 mAb was added to the culture medium. The
reduction was statistically significant at 1–10 mg/ml of SHPS-1-Fc (**Po0.01;
n¼ 6) and at 0.05–5mg/ml of anti-CD47 mAb (**Po0.05; n¼ 6). Error bars
indicate SDs. (c) Pertussis toxin (PT; 100 ng/ml) restored the inhibition
of the chemotaxis by SHPS-1-Fc treatment (**Po0.01; n¼6). Error bars
indicate SDs.
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explant culture mimics the effect of hapten application on
changes in epidermal LCs, that is, enhanced motility and an
increased expression of costimulatory molecules. Our finding
that the engagement of CD47 suppresses costimulatory
molecules on LCs is in accordance with the observation that
engagement with a CD47 mAb inhibits the maturation of
human DCs, which includes the expression of CD80 and
CD86, resulting in T-cell anergy (Demeure et al., 2000; Avice
et al., 2001). As the expression of B7 molecules on LCs seems
to be indispensable in antigen presentation during the
sensitization phase of CHS, the CHS response could be
impaired by the downregulation of these two costimulatory
molecules and/or the suppression of LC motility by CD47
engagement. Because it is well known that B7 molecules are
expressed during the maturation of DCs including LCs, the
engagement of CD47 with SHPS-1 may downregulate the
maturation of LCs.
CD47 is expressed on various cell types including LCs and
keratinocytes, suggesting that in vivo injection of SHPS-1-Fc
may bind to all these cells. The engagement of CD47 on
keratinocytes or LCs by SHPS-1-Fc appears to suppress the
migration of LCs, because SHPS-1-Fc decreases the migration
of LCs from explant cultures of epidermis where no other
cells are present that could influence the motility of LCs.
Further, treatment with SHPS-1-Fc or a CD47 mAb reduced
the transmigration of XS52 cells stimulated with MIP-3b,
which suggests that the direct engagement of CD47 on DCs
inhibits their motility rather than affecting surrounding cells.
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Figure 7. SHPS-1-Fc reduced the expression of CD80 and CD86 on epidermal LCs during skin explant culture. Epidermal explants were cultured for 24 hours
with SHPS-1-Fc or control human IgG-Fc, and the expression of I-Ab (green) and CD86 (red) was then evaluated using immunofluorescence. (a) The lowest
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This observation also suggests that chemokine-induced LC
migration is modulated by CD47 engagement. The evidence
that the TNF-a-driven migration of LCs is suppressed by
treatment with SHPS-1-Fc suggests that SHPS-1-Fc suppresses
LC migration following TNF-a signaling rather than inhibiting
TNF-a production by keratinocytes. Taken together, the
results imply that the inhibitory effect of in vivo treatment
with SHPS-1-Fc on LC motility is mediated via the direct
binding of SHPS-1-Fc with CD47 on LCs. This is compatible
with the observation that engagement of CD47 with a CD47
mAb or 4N1K reduces the transmigration of neutrophils
(Cooper et al., 1995; Parkos et al., 1996). Because
thrombospondin-1 is another ligand for CD47, and down-
regulates DC functions including cytokine production (Doyen
et al., 2003), it is possible that CD47 ligation by thrombo-
spondin-1 also modulates LC functions, including motility.
The inhibitory effect of treatment with SHPS-1-Fc on the
induction of CHS was reversed by pretreatment with pertussis
toxin. Pretreatment with pertussis toxin and subsequent
treatment with SHPS-1-Fc reversed the downregulation of
motility and the expression of B7 costimulatory molecules by
LCs. The inhibitory effect of CD47 engagement by SHPS-1-Fc
on the development of CHS and the modification of LCs is
thus mediated via Gi/o protein. Although it is clear that
pertussis toxin enhances the responses of CHS and delayed-
type hypersensitivity (Gamble et al., 1983; Sewell et al.,
1983; Roberts et al., 1985), the mechanism(s) of the pertussis
toxin-induced enhancement of CHS and delayed-type
hypersensitivity is not understood. In the epidermis, CD47
and SHPS-1 on different LCs may bind to each other via their
dendrites or both on the same LC may interact in a cis fashion
(Zen and Parkos, 2003). Furthermore, it has been shown that
SHPS-1 is shed from the plasma membrane, suggesting that
soluble SHPS-1 may bind to CD47 (Ohnishi et al., 2004). The
engagement of CD47 with SHPS-1 may signal LCs in a Gi
protein-dependent manner to downregulate their motility,
their expression of costimulatory molecules, and/or conse-
quently suppress the CHS response. We therefore assume that
the enhancing effect of pertussis toxin on the sensitization of
CHS is, at least in part, via inhibition of the CD47/Gi
complex-mediated signaling, which suppresses LC migration
as well as the expression of B7 molecules.
On the other hand, in the case of human neutrophils,
which express SHPS-1/SIRPa, the binding of CD47 and SHPS-
1/SIRPa is required in the transmigration through epithelial
and endothelial tissues (Cooper et al., 1995; Parkos et al.,
1996; Liu et al., 2001). CD47-null mice have been shown to
develop E. coli sepsis because of a delayed recruitment of
neutrophils to the infected organ (Lindberg et al., 1996).
Thus, CD47 seems to be a prerequisite molecule in
neutrophil transmigration through epithelial and endothelial
organs. Ligation of CD47 in vivo by exogenously injected
SHPS-1-Fc may interfere with the CD47-SHPS-1 interaction
and thereby affect the migration of LCs. Because keratino-
cytes express SHPS-1 at very low levels, SHPS-1-Fc blocks
the binding of CD47 on keratinocytes and SHPS-1 on LCs.
Previously, we showed that engagement of SHPS-1 on LCs
attenuates the motility of LCs, suggesting that the binding of
SHPS-1 to CD47 on keratinocytes downregulates LC migra-
tion (Fukunaga et al., 2004). If this is the case, the
engagement of CD47 on keratinocytes with SHPS-1-Fc and
the consequent reduction of the ligation of SHPS-1 on LCs
might prevent the downregulation of LC migration. However,
treatment with SHPS-1-Fc in vivo suppresses the migration of
LCs. We therefore speculate that blocking the binding of
SHPS-1 and CD47 may not affect the suppression of LC
motility.
CD47–SHPS-1 interaction may induce a firm adhesion,
resulting in the aggregation of cells (Babic et al., 2000).
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Because the migration of LCs requires their detachment from
keratinocytes, it is possible that firm adhesion between LCs
and keratinocytes may disturb the detachment and the
subsequent migration of LCs. Very recently, it has been
shown that CD47-expressing cells firmly adhere to other
CD47-expressing cells without interacting with SHPS-1/SIRPa
or with thrombospondin-1 (Rebres et al., 2005). A possible
homophilic binding of CD47 molecules is proposed as a
mechanism for this CD47-mediated aggregation of cells. This
firm adhesion is inhibited by pertussis toxin, suggesting that
Gi/o protein–CD47-associated signaling is involved. The
engagement of CD47 with 4N1K upregulates the CD47-
dependent cell–cell adhesion, whereas binding with a CD47
mAb (2D3) inhibits the adhesion (Rebres et al., 2005).
Whether CD47-dependent adhesion between LCs and
keratinocytes is enhanced by the ligation of CD47 with
SHPS-1-Fc is so far unclear, and should be further studied.
The engagement of CD47 has been shown to modulate
antigen presentation in vitro. The engagement of CD47 by a
CD47 mAb and by 4N1K inhibits the proliferation of
lymphocytes in mixed lymphocyte reaction or induces anergy
(Avice et al., 2001). Recently, SIRPb2 has been found to be a
new ligand for CD47. SIRPb2 lacks an immunoreceptor with
tyrosine-based inhibition motif in its sequence and is
expressed by T cells. The binding of SIRPb2 on T cells and
CD47 on DCs costimulates the proliferation of T lymphocytes
(Piccio et al., 2005). Treatment with SHPS-1-Fc in vivo may
inhibit the binding of these two molecules in secondary
lymphoid tissues, and thereby it may prevent the develop-
ment of CHS. Thus, a possible inhibitory effect of SHPS-1-Fc
on SIRPb2-mediated antigen presentation suggests a further
mechanism for SHPS-1-Fc to inhibit the development of CHS.
In conclusion, we show in this study that in vivo treatment
with a CD47 ligand, SHPS-1-Fc, reduces the development of
CHS, as well as the motility and costimulatory molecule
expression of LCs. As the engagement of SHPS-1 by CD47
also inhibits LC migration, SHPS-1–CD47 mutually inhibits
the functions of LCs in the development of CHS.
MATERIALS AND METHODS
Mice
Female C57BL/6 mice (6–8 weeks old) were purchased from Charles
River Japan (Tokyo, Japan). All animals were maintained in
microisolator cages and were exposed to a 12-hours light/12-hours
dark cycle, with standard feed and water ad libitum. All animal
experiments were conducted according to the Guidelines for Animal
Experimentation at the Kobe University Graduate School of
Medicine.
Cells
XS52 cells, a long-term DC line established from murine newborn
epidermis (Xu et al., 1995), were provided by Dr A. Takashima
(University of Texas, Dallas, TX). XS52 cells were cultured in
medium composed of complete RPMI (RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine,
10 mM HEPES, 100 mM nonessential amino acids, 1 mM sodium pyru-
vate, 5 105 M 2-mercaptoethanol (Nacalai Tesque, Tokyo, Japan),
and 1% penicillin/streptomycin/amphotericin B (Bio-Whittaker Inc.,
Walkersville, MD)) supplemented with 2 ng/ml murine rGM-CSF
(Strathmann Biotec, Hamburg, Germany) and culture supernatant
(10%, v/v) from NS47 stromal cells (also provided by Dr A.
Takashima). To induce the maturation of XS52 cells, they were
cultured in complete RPMI supplemented with 10 ng/ml murine
rGM-CSF and 10 ng/ml murine rIL-4 (RELIATech, Braunschweig,
Germany) (Yamada and Katz, 1999). After 6 days, XS52 cells were
cultured for an additional 3 days in the presence of rGM-CSF and rIL-
4. A human melanoma cell line, G361, was maintained in our
laboratory, and cultured in MEM supplemented with 10% heat-
inactivated fetal bovine serum (Oka et al., 1996).
Antibodies and reagents
A rat mAb to mouse CD47 (MIAP 301) was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Phycoerythrin (PE)- or FITC-
conjugated mouse anti-mouse I-Ab mAb (AF6-120.1) was purchased
from BD Bioscience (Tokyo, Japan). Rabbit polyclonal antibody
raised against mouse Langerin peptide (ab22111) was from Abcam
(Cambridge, UK). FITC-conjugated goat anti-rat IgG F(ab0)2 and rat
IgG were obtained from Wako Pure Chemical Industries (Osaka,
Japan) and Sigma-Aldrich (St Louis, MO), respectively. PE-conju-
gated rat anti-mouse CD80 mAb and PE-conjugated rat anti-mouse
CD86 mAb were from Immunotech (Marseille Cedex, France). PE-
conjugated sheep anti-rabbit IgG was from Oxford Biotechnology
(Kidlington, UK). Mouse SHPS-1-Fc, a chimera protein of mouse
SHPS-1 and Fc portion of human IgG, was generated as previously
described (Motegi et al., 2003). Briefly, CHO-Ras cells were
transfected with pTracerCMV-mSHPS-1-Fc. The SHPS-1-Fc fusion
protein was then purified from the culture supernatant by column
chromatography on Protein A-Sepharose 4FF (Amersham Pharmacia
Biotech, Uppsala, Sweden). The human IgG-Fc fragment was
obtained from Jackson ImmunoResearch Laboratories (West Grove,
PA). FITC-conjugated goat affinity-purified F(ab0)2 fragments to
human IgG were purchased from ICN Pharmaceuticals (Aurora,
CA). Pertussis toxin was purchased from List Biological Laboratories
(Campbell, CA).
Flow cytometry analysis
Epidermal cell suspensions were obtained from mouse ears as
previously described (Fukunaga et al., 2004). The suspensions
(5 105/ml) were incubated on ice for 30 minutes with PE-
conjugated mouse anti-mouse I-Ab mAb and rat anti-mouse CD47
mAb or SHPS-1-Fc, each at a 1/100 dilution in RPMI 1640, and were
then washed with RPMI 1640. The suspensions were further
incubated on ice for 30 minutes with FITC-conjugated goat anti-rat
IgG F(ab0)2 or with FITC-conjugated goat anti-human IgG (whole
molecule), each diluted 1/100 in RPMI 1640. The XS52 cells
(1 106/ml) were incubated on ice for 30 minutes with rat IgG and
rat anti-mouse CD47 mAb, each diluted 1/100 in RPMI 1640, and
were then washed with RPMI 1640. The cells were further incubated
on ice for 30 minutes with FITC-conjugated goat anti-rat IgG F(ab0)2
(1/100). After a final washing with RPMI 1640, the samples were
analyzed using a FACSCalibur flow cytometer and CellQuest (BD
Biosciences, San Jose, CA). To examine if engagement of CD47 by
SHPS-1-Fc inhibits the binding of CD47 mAb, XS52 cells were
preincubated with SHPS-1-Fc for 30 minutes and then were incu-
bated with the CD47 mAb, followed by incubation with FITC-conjugated
goat anti-rat IgG F(ab0)2.
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Preparation of murine epidermal sheets and
immunofluorescence analysis
Epidermal sheets were obtained as previously described (Fukunaga
et al., 2004). Ears were split into dorsal and ventral halves with the
aid of forceps. The dorsal ear halves were incubated with 2 M NaBr
for 2 hours at 371C. The epidermis was then separated from the
dermis using forceps and was washed in phosphate-buffered saline
(PBS). Epidermal sheets were fixed in cold acetone for 3–5 minutes at
201C. After fixation, the sheets were washed in PBS and were then
incubated at room temperature for 30 minutes with FITC-conjugated
mouse anti-mouse I-Ab mAb and PE-conjugated rat anti-mouse
CD80 mAb or PE-conjugated rat anti-mouse CD86 mAb, each
diluted 1/100 in 5% BSA/PBS. The sheets were finally washed with
PBS and mounted on microscope slides in PermaFluor (Shandon,
Pittsburgh, PA). The samples were analyzed using a Fluoview
confocal laser scanning microscope (Olympus, Nagano, Japan). The
number of LCs seen in the epidermis was counted in 10 fields/sample
for each experimental condition.
Contact hypersensitivity and histological examination
CHS response was assessed as previously described with a slight
modification (Ando et al., 2000). Sensitization was induced on day 0
by applying 10 ml of DNFB solution (0.5% in acetone/olive oil, 4/1)
to the dorsal aspect of each right ear. After 5 days, 10 ml of 0.2%
DNFB solution was applied to the dorsal surface of each left ear.
Nonsensitized mice were evaluated in parallel to determine the skin
irritant component of the DNFB challenge solution. Ear swelling was
measured in a blinded fashion with a digimatic micrometer
(Mitutoyo, Kawasaki, Japan) 24 hours after challenge. To investigate
the effects of in vivo SHPS-1-Fc treatment on CHS, 60 mg SHPS-1-Fc
or control human IgG-Fc in 30 ml PBS was injected intradermally into
the right dorsal ear just before sensitization. Some mice that were
treated with SHPS-1-Fc were intradermally injected with 30 ml of
3.3 mg/ml pertussis toxin or 30 ml of control PBS 2 hours before the
SHPS-1-Fc treatment. Each group consisted of at least five mice. Ear
tissues were surgically removed from mice immediately after
determination of ear swelling, fixed in 10% formalin, and then
processed and stained with hematoxylin and eosin.
FITC-bearing LC migration assay
FITC (Wako Pure Chemical Industries, Osaka, Japan) was dissolved
in acetone/dibutylphthalate (1/1) before application. Mice were
painted on both the dorsal and ventral ear halves with 25 ml of 3%
FITC solution. The SHPS-1-Fc fusion protein and human IgG-Fc were
injected intradermally at a dose of 60 mg/ear before the FITC
application. Twenty-four hours after FITC painting, draining auri-
cular lymph nodes were collected, placed in RPMI 1640, and teased
into single-cell suspensions before total cell counts and viability
were checked using 0.2% Trypan blue (Sigma-Aldrich). Single-cell
suspensions were incubated on ice for 30 minutes with PE-
conjugated mouse anti-mouse I-Ab mAb, diluted 1/100 in RPMI
1640. After a final washing with RPMI 1640, the samples were
analyzed using a FACSCalibur flow cytometer and CellQuest. For
intracellular staining of Langerin, we used the saponin technique
(Ohl et al., 2004). We fixed the lymph node cells with 0.5%
paraformaldehyde for 10 minutes on ice, followed by treatment with
0.1% saponin in PBS containing 3% FCS for 15 minutes at room
temperature. The cells were then incubated with anti-mouse
Langerin polyclonal antibody (1:100 dilution) on ice for 30 minutes,
washed, and incubated with PE-conjugated anti-rabbit IgG (1:50
dilution) on ice for 30 minutes. After the final washing, samples were
analyzed by FACSCaliber. The numbers of migrated FITC bearing-I-
Abþ cells in the draining lymph nodes were calculated using the
following formula: the numbers of migrated FITC bearing cells¼ (the
number of cells in the lymph node)(the percentage of FITC-bearing
I-Abþ or FITC-bearing Langerinþ cells)/100.
TNF-a-induced LC migration assay
Groups of mice (n¼ 5) received intradermal injections of 30ml of
mouse rTNF-a (Sigma-Aldrich; 60 ng/ear) or an equivalent volume of
carrier protein (0.1% BSA) into ear pinnae with 30-gauge stainless steel
needles. SHPS-1-Fc or control human IgG-Fc was injected intrader-
mally at a dose of 60mg/ear simultaneously. The ears were collected for
staining of LCs 1 hour after the injection (Cumberbatch et al., 1997b).
Epidermal skin organ culture
Epidermal skin organ culture was performed as previously described
(Ratzinger et al., 2002). Ears cutoff from mice were rinsed in 70%
ethanol for 10 seconds and were then split into dorsal and ventral
halves. The epidermis was separated from the dermis by incubation
of the dorsal halves of the ears in dispase II (1.2 U/ml; Roche,
Penzbeg, Germany) for 30 minutes before the onset of culture
(Fukunaga et al., 2004). These pieces of epidermis were cultured in
24-well tissue culture plates in 1.5 ml of 10% fetal bovine serum
RPMI 1640 for 48 hours at 371C. At least six explants were cultured
for each experimental condition. The cells that had emigrated into
the culture medium during this time were counted. In some
experiments, emigrated cells were collected and incubated at room
temperature for 30 minutes with FITC-conjugated mouse anti-mouse
I-Ab mAb and PE-conjugated rat anti-mouse CD80 mAb or PE-
conjugated rat anti-mouse CD86 mAb, each diluted 1/100 in 5%
BSA/PBS. The samples were analyzed using a FACSCalibur flow
cytometer and CellQuest.
Chemotaxis
Chemotaxicells (5mm pore size; Kurabo, Osaka, Japan) were
pretreated with 5mg/ml laminin (Sigma-Aldrich) for 40 minutes at
room temperature. XS52 cells (5 104) were then added to the upper
chamber of each chemotaxicell, and 50 ng/ml murine rMIP-3b
(Genzyme/Techne, Minneapolis, MN) was added to the lower
chamber. After incubation for 4 hours at 371C, the membranes of the
chemotaxicells were removed, fixed with methanol, and stained
with Giemsa. The number of cells that had transmigrated toward the
lower chamber was counted using a microscope.
Statistical analysis
The statistical significance of differences between the means was
determined using the two-tailed Student’s t-test. A difference is
considered statistically significant at Po0.05. Each experiment was
performed at least two times.
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